About Moscow Regional Oncological Dispensary ( Site 2028)
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at Moscow Regional Oncological Dispensary ( Site 2028)
During the past decade, Moscow Regional Oncological Dispensary ( Site 2028) conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer
2009-05-01
2010-05-01
Completed
15
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
2011-07-06
2021-07-30
Completed
1,401
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
2011-12-20
2018-06-02
Completed
692
TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
2012-08-24
2022-05-31
Completed
717
A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)
2012-12-03
2017-05-31
Terminated
182
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Moscow Regional Oncological Dispensary ( Site 2028)
According to Clinical.Site data, the most researched conditions in "Moscow Regional Oncological Dispensary ( Site 2028)" are
"Carcinoma, Non-squamous Non-small-cell Lung" (1 trials) and "Carcinoma, Squamous Cell, Non-small-cell Lung" (1 trials). Many other conditions were trialed in "Moscow Regional Oncological Dispensary ( Site 2028)" in a lesser frequency.
Clinical Trials Intervention Types at Moscow Regional Oncological Dispensary ( Site 2028)
Most popular intervention types in "Moscow Regional Oncological Dispensary ( Site 2028)" are "Biological" (2 trials) and "Drug" (2 trials). Other intervention types were less common.
The name of intervention was led by "Carboplatin" (2 trials), "Olaparib" (2 trials), "Pembrolizumab" (2 trials), "Cisplatin" (1 trials) and "Nab-paclitaxel" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Moscow Regional Oncological Dispensary ( Site 2028)
The vast majority of trials in "Moscow Regional Oncological Dispensary ( Site 2028)" are
2 trials for "All" genders.
Clinical Trials Status at Moscow Regional Oncological Dispensary ( Site 2028)
Currently, there are NaN active trials in "Moscow Regional Oncological Dispensary ( Site 2028)".
undefined are not yet recruiting,
undefined are recruiting,
2 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Moscow Regional Oncological Dispensary ( Site 2028),
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Moscow Regional Oncological Dispensary ( Site 2028), 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".